StockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss
Lilly now expects to rack up between $85 billion and $87 billion in revenue this year, up 2.4% to 3.7% from its previous range of between $82 billion and $85 billion. That change raised the midpoint of Lilly’s revenue forecast from $85.5 billion to $86 billion. The post StockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss appeared first on GEN - Genetic…
Eli Lilly demonstrated strong financial performance in its second quarter, surpassing analyst expectations with robust revenue growth and impressive earnings. The company's tirzepatide products, Zepbound and Mounjaro, drove significant revenue increases, with Mounjaro's sales more than doubling to $9.943 billion, a 91% rise from the previous quarter.
Lilly's revenue for the quarter climbed 48% to $22.974 billion, up from $15.558 billion in the same period last year. Despite a slight adjustment to its high-end earnings per share (EPS) guidance, Lilly reaffirmed its confidence in its 2026 revenue forecast, projecting between $85 billion and $87 billion. Analysts, including David Risinger from Leerink Partners, praised Lilly's performance, attributing its success to the company's operating leverage and the strong sales of its adult type 2 diabetes drug Mounjaro.
The company's chairman and CEO, David A. Ricks, expressed optimism about Lilly's future, highlighting the potential of its next-generation obesity drug, retatrutide, and ongoing manufacturing expansions.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
